BackABL Diagnostics Société anonyme Overview

ABL Diagnostics Société anonyme EBIT

Latest ebit for ABLD.PA: $480K, below the sector sector average of $2.6T.

Get informed when a big investor buys or sells

+ Follow

Quarterly EBIT

-$17.32K
↓ 103.24% YoY

As of Jun 30, 2019

Annual EBIT (TTM)

$482.81K
↓ 54.32% YoY

Trailing 12 months ending Jun 30, 2019

Average EBIT (Comparison Companies)

EBIT History

EBIT Comparison

Annual EBIT Growth Rate (%)

Annual EBIT Growth (Absolute)

ABL Diagnostics Société anonyme (ABLD.PA) FAQ

The latest EBIT for ABLD.PA is $480K as of June 2019. That compares with $1.1M in the prior-year period — down 54.3% year over year. That is below the sector sector average of $2.6T. Investors often review this figure alongside ABL Diagnostics Société anonyme's historical trend and sector peers before judging valuation or financial health.

Over the past year, ABLD.PA's EBIT moved from $1.1M to $480K — a 54.3% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in ABL Diagnostics Société anonyme's operating scale or balance-sheet position.

Against its sector companies, ABLD.PA currently prints $480K for EBIT, while the sector average sits near $2.6T. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at ABL Diagnostics Société anonyme's growth, margins, and balance sheet.

A EBIT figure of $480K for ABLD.PA is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The sector average is about $2.6T. Explore the charts below for those layers of context.

After noting ABLD.PA's EBIT ($480K), review year-over-year change from $1.1M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.